Biogen to Acquire RayThera for Up to $1 Billion, Expanding Immunology Portfolio

Biogen Inc. signed a definitive agreement to acquire private biotech RayThera Inc. for up to $1 billion. The deal includes an undisclosed upfront cash payment, with most of the consideration tied to future clinical and regulatory milestones. Closing is targeted for Q3 2026, pending regulatory approvals. After closing, Biogen will oversee development, manufacturing, and global commercialization of RayThera’s anti-inflammatory small-molecule programs, including a lead candidate set to start Phase 1 in early Q3 2026.

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.BenzingaPharmaphorumBioPharmaDive

Biogen, a neurology leader, has been expanding into immunology. In 2025 it bought Apellis Pharmaceuticals for $5.6 billion, adding complement-targeted therapies, and in early 2026 signed a deal with Alloy Therapeutics for antisense programs. The RayThera acquisition adds early-stage small-molecule anti-inflammatory candidates, broadening Biogen’s immune-mediated disease portfolio.

BenzingaBioPharmaDivePharmaphorumBiogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen’s announcement was made by Priya Singhal, EVP and Head of Development. RayThera’s co-founders are Qing Dong (Chairman, CEO) and Gene Hung. The 2025 Series A round was led by Foresite Capital and OrbiMed Advisors.

Pharmaphorum

The acquisition supplies Biogen with multiple anti-inflammatory candidates, diversifying revenue beyond its neurology franchise, which faces biosimilar competition and mixed Alzheimer’s data. Analysts project $300 billion in exclusivity losses this decade; the new assets help offset that pressure and expand Biogen’s therapeutic reach.

Benzinga

Biogen said the deal deepens its immunology pipeline and enables rapid clinical progression, while stressing a balanced risk-return approach for long-term growth. RayThera’s leaders expressed confidence in Biogen’s global development capabilities.

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Observers criticize the deal’s opacity, noting the undisclosed upfront payment and limited detail on the pipeline candidates. The acquisition also occurs amid biosimilar pressure on Biogen’s neurology products.

Benzinga

All sources agree on a $1 billion ceiling and Q3 2026 closing, but none reveal the exact upfront amount or candidate names. Patent filings list target classes only.

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

• “With this acquisition, we are further deepening our pipeline in immunology by adding a suite of assets that can allow us to expand into new disease areas,” — Priya Singhal, M.D., M.P.H., Executive Vice President, Biogen

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

• “We believe these assets can meaningfully contribute to our long-term pipeline potential and we’re excited about the opportunity to rapidly advance the first candidate into the clinic.” — Priya Singhal, Biogen

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

• “With its strong global development capabilities in immunology, we believe that Biogen is the natural fit to move these assets forward into Phase 1 development and beyond,” — Qing Dong, Co-founder, Chairman & CEO, RayThera

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

• “Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.” — Biogen corporate statement

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

• “impressed with the progress” — Michael Rome, Partner, Foresite Capital

BioPharmaDive

Biogen expects the transaction to close in Q3 2026. The lead anti-inflammatory candidate will enter Phase 1 in early Q3 2026, triggering milestone payments tied to trial outcomes and regulatory approvals.

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.